DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for testicular seminoma — screening already-approved drugs against its 46-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleTesticular seminoma maps to a 46-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for testicular seminoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
NRAS proto-oncogene, GTPase (NRAS) — NRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gdpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6ZIO · 1.55 Å · ligand GUANOSINE-5'-DIPHOSPHATE (GDP). Experimental structure, not a prediction.
What the evidence adds up to
Between April 1962 and March 1984, 61 patients with testicular seminoma were seen at one hospital; 52 had long-term follow-up after megavoltage irradiation. Thirty patients had stage I disease, 21 had stage II, and one had stage III. The overall relapse-free survival rate for all stages was 92%, with an adjusted survival rate of 96%. No drug treatment was involved.
Two case reports from 2000 describe the phenomenon of spontaneous regression of a primary testicular seminoma, termed 'shrinking seminoma'. These cases illustrate that reduction in testicle size, like enlargement, warrants investigation for malignancy. The aetiology of this regression is discussed but not established in the reports.
A third abstract, dated 2007, is a French-language article on Montpellier wills from 1554–1622. It contains no data on testicular seminoma, no drug, and no treatment. It appears to have been incorrectly retrieved.
What is still missing: no drug-repurposing data exist in these abstracts. There are no randomised trials, no molecular stratification, and no funding for a drug-repurposing study in seminoma. The 1987 results are from radiotherapy alone, not a drug.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Clinical Oncology · 1987 · 8 citations
Testicular Seminoma Results of a Program of Mega voltage Irradiation
AbstractBetween April 1962 and March 1984, 61 patients with a diagnosis of testicular seminoma were seen at Hahnemann University Hospital. Of these patients, 52 had long-term follow-up after definitive treatment with megavoltage irradiation. In 30 patients, disease was classified as stage I, in 21 patients, stage II, and in one patient, stage III. Treatment techniques are described. Overall relapse-free survival rate for all stages was 92% with an adjusted survival rate of 96%. Treatment policies for each stage are presented.
AbstractWe report 2 cases of testicular seminoma with unusual but dissimilar clinical presentations, which may represent different stages of spontaneous regression of a primary testicular seminoma, the so-called 'shrinking seminoma'. The aetiology of this phenomenon is discussed. These cases also illustrate that, like enlargement, reduction in the size of a testicle warrants investigation for malignancy.
L'enseigment des testaments montpelliérains (1554-1622)
AbstractBetween April 1962 and March 1984, 61 patients with a diagnosis of testicular seminoma were seen at Hahnemann University Hospital. Of these patients, 52 had long-term follow-up after definitive treatment with megavoltage irradiation. In 30 patients, disease was classified as stage I, in 21 patients, stage II, and in one patient, stage III. Treatment techniques are described. Overall relapse-free survival rate for all stages was 92% with an adjusted survival rate of 96%. Treatment policies for each stage are presented.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
